Multiples Myelom (Plasmozytom)

  • F. J. Giles
  • B. G. M. Durie

Zusammenfassung

Es wurde über eine statistische Assoziation zwischen HLA-CwA und HLA-Cw2 und der Entwicklung eines Myeloms berichtet. Der Nachweis einer Translokation t(8,14) (q24; q32) ist mit Expression des IgA-Paraproteins assoziiert; Abberationen am Chromosom 14 treten bei 1/3 der Patienten mit zytogenetischen Abnormalitäten auf. Die Bedeutung einer Expression von bcl-1 und bcl-2 ist ungeklärt. Gelegentlich findet sich eine Überexpression des c-myc Protoonkogens.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ries LAG, Hankey BF, Miller BA et al. (1991) Cancer Statistics Review 1973–1988 (DHSS pubi [NIHI no 91–2789 ). Washington, DC, US Govt Printing OfficeGoogle Scholar
  2. 2.
    Cuzick J (1990) International time trends for multiple myeloma. Ann NY Acad Sci 609: 205PubMedCrossRefGoogle Scholar
  3. 3.
    Davis DL, Hoel D, Fox J et al. (1990) International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet 2: 474Google Scholar
  4. 4.
    Shimizu Y, Kato H, Schull W (1990) Studies on the mortality of A-bomb survivors. 9. Mortality 1950–1985: Part 2 Cancer mortality based on the recently revised doses (DS86). Radiat Res 121: 120PubMedCrossRefGoogle Scholar
  5. 5.
    Matanoski GM (1982) Risk of cancer associated with occupational exposure in radiologists and other radiation workers. In: Burchenal JH, Ottegen HF (eds) Cancer, Achievements, Challenges, and Prospects for the 1980’s. Grune Stratton, New York, p 241Google Scholar
  6. 6.
    Stebbings JH, Lucas HF, Stehney AF (1984) Mortality from cancers of major sites in female radium dial workers. Am J Ind Med 5: 435PubMedCrossRefGoogle Scholar
  7. 7.
    Smith PG, Douglas AJ (1986) Mortality of the workers at Sellafield plant of British Nuclear Fuels. Br Med J 293: 845CrossRefGoogle Scholar
  8. 8.
    Gilbert ES, Fry SA, Wiggs DL et al. (1989) Analyses of combined mortality data at the Hanford Site, Oak Ridge National Laboratory, and Rocky Flats Nuclear Weapons Plant. Radiat Res 120: 19Google Scholar
  9. 9.
    Darby SC, Kendall GM, Fell TP et al. (1988) A summary of mortality and incidence of cancer in men who participated in the United Kingdom’s atmospheric nuclear weapons tests and experimental programmes. Br Med J 296: 332CrossRefGoogle Scholar
  10. 10.
    Riedel DA, Pottern LM, Blattner WA (1991) Epidemiology of multiple myeloma. ln: Wimik PH, Canellos GP, Kyle RA, Schiffer CA (eds) Neoplastic Diseases of the Blood, ed 2. Churchill Livingstone, New York, p 347Google Scholar
  11. 11.
    Burmeister LF, Everett GD, Van Lier SF, Isacson P (1983) Selected cancer mortality and farm practices in Iowa. Am J Epidemiol 118: 72PubMedGoogle Scholar
  12. 12.
    Reif J, Pearce N, Fraser J (1989) Cancer risks in New Zealand farmers. Int J Epidemiol 18: 768PubMedCrossRefGoogle Scholar
  13. 13.
    Pearce NE, Smith AH, Howard JK et al. (1986) Case-control study of multiple myeloma and farming. Br J Cancer 54: 493PubMedCrossRefGoogle Scholar
  14. 14.
    Ott MG, Teta MJ, Greenberg HL (1989) Lymphatic and hematopoietic tissue cancer in a chemical manufacturing environment. Am J Ind Med 16: 631PubMedGoogle Scholar
  15. 15.
    Cuzick J, De Stavola B (1988) Multiple myeloma — a case-control study. Br J Cancer 57: 516PubMedCrossRefGoogle Scholar
  16. 16.
    Linet MS, Harlow SD, McLaughlin JK (1987) A case-control study of multiple myeloma in whites: Chronic antigenic stimulation, occupation, and drug use. Cancer Res 47: 2978Google Scholar
  17. 17.
    McLaughlin JK, Malker HS, Linet MS et al. (1988) Multiple myeloma and occupation in Sweden. Arch Environ Health 43: 7PubMedCrossRefGoogle Scholar
  18. 18.
    Morris PD, Koepsell TD, Daling JR et al. (1986) Toxic substance exposure and multiple myeloma: A case-control study. J Natl Cancer Inst 76: 987Google Scholar
  19. 19.
    Siemiatycki J (1991) Risk factors for Cancers in the Workplace. CRC Press, Boca Raton, FloridaGoogle Scholar
  20. 20.
    Spinelli JJ, Gallagher RP, Band PR, Threlfall WJ (1984) Multiple myeloma, leukemia, and cancer of the ovary in cosmetologists and hairdressers. Am J Ind Med 6: 197CrossRefGoogle Scholar
  21. 21.
    Bethwaite PB, Pearce N, Fraser J (1990) Cancer risks in painters: Study based on the New Zealand Cancer Registry. Br J Ind Med 47: 742Google Scholar
  22. 22.
    Leech SW, Brown R, Schanfield MS (1985) Genetic studies in multiple myeloma. ll. Immunoglobulin allotype associations. Cancer 55: 1473Google Scholar
  23. 23.
    Gould J, Alexanian R, Goodacre A et al. (1988) Plasma cell karyotype in multiple myeloma. Blood 71: 453PubMedGoogle Scholar
  24. 24.
    Nobuyoshi M, Kawano M, Tanaka H et al. (1991) Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br J Haematol 77: 523PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson KC, Jones RM, Morimato C et al. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73: 1915PubMedGoogle Scholar
  26. 26.
    Jackson N, Ling MR, Ball J et al. (1988) An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd international workshop on human leucocyte differentiation antigens. Clin Exp Immunol 72: 351PubMedGoogle Scholar
  27. 27.
    Pilarski M, Mant MJ, Reuther BA (1985) Pre-B cells in peripheral blood of multiple myeloma patients. Blood 66: 416PubMedGoogle Scholar
  28. 28.
    Hamilton MS, Ball J, Bromidge E et al. (1991) Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol 78: 60PubMedCrossRefGoogle Scholar
  29. 29.
    Drewinko B, Alexanian R, Boyer H et al. (1981) The growth fraction of human myeloma cells. Blood 57: 333PubMedGoogle Scholar
  30. 30.
    Kawano M, Hirano T, Matsuda T et al. (1988) Autocrine generation and requirement of BSF2/IL-6 for human multiple myelomas. Nature 332: 83PubMedCrossRefGoogle Scholar
  31. 31.
    Klein B, Zhang X-G, Jourdan M et al. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517PubMedGoogle Scholar
  32. 32.
    Bataille R, Klein B (1991) The bone resorbing activity of interleukin-6. J Bone Miner Res 9: 1144Google Scholar
  33. 33.
    Caligaris-Cappio F, Bergui L, Gregoretti MG et al. (1991) Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77: 2688PubMedGoogle Scholar
  34. 34.
    Bataille R, Chappard D, Marcelli C et al. (1991) The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88: 62PubMedCrossRefGoogle Scholar
  35. 35.
    Dune BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842Google Scholar
  36. 36.
    Dude BGM, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55: 364Google Scholar
  37. 37.
    Dude BGM, Stock-Novack D, Salmon SE et al. (1990) Prognostic value of pretreatment serum N microglobulin in myeloma: a Southwest Oncology Group study. Blood 75: 823Google Scholar
  38. 38.
    Dude BGM, Grogan TM (1985) CALLA-positive myeloma: An aggressive subtype with poor survival. Blood 66: 229Google Scholar
  39. 39.
    Barlogie B, Smallwood L, Smith T et al. (1989) High serum levels of Lactic Dehydrogenase identify a High-Grade lymphoma-like myeloma. Ann Int Med 110: 521PubMedCrossRefGoogle Scholar
  40. 40.
    Carlson K, Ljunghall S, Simonsson B et al. (1992) Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survival. J Internal Med 231: 133PubMedCrossRefGoogle Scholar
  41. 41.
    Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334PubMedGoogle Scholar
  42. 42.
    Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33: 86PubMedCrossRefGoogle Scholar
  43. 43.
    Samson D, Gaminara E, Newland A et al. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2: 882PubMedCrossRefGoogle Scholar
  44. 44.
    Alexanian R, Dimopoulus MA, Delasalle K et al. (1992) Primary Dexamethasone treatment of multiple myeloma. Blood 80: 887PubMedGoogle Scholar
  45. 45.
    Dude BGM, Dixon DO, Carter S et al. (1986) Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 4: 1227Google Scholar
  46. 46.
    Boccadoro M, Marmont F, Tribalto M et al. (1991) Multiple myeloma: VMCPNBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9: 444Google Scholar
  47. 47.
    Bladé J, San Miguel J, Alcalà A et al. (1990) A randomized multicentric study comparing alternating combination chemotherapy ( VCMPNBAP) and melphalan-prednisone in multiple myeloma. Blut 60: 319Google Scholar
  48. 48.
    Oken MM, Kyle RA, Greipp PR et al. (1992) Possible survival benefit with chemotherapy plus interferon (rIFNab) in the treatment of multiple myeloma. ASCO Proc 11: 358Google Scholar
  49. 49.
    Osterborg A, Björkholm M, Björeman M et al. (1993) Natural interferon-a in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma Stages II and Ill: a randomized study from the Myeloma Group of Central Sweden. Blood 81: 1428PubMedGoogle Scholar
  50. 50.
    Gahrton G, Tura S, Ljungman P et al. (1991) Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325: 1267PubMedCrossRefGoogle Scholar
  51. 51.
    Jagannath S, Barlogie B, Dicke K et al. (1990) Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 76: 1860PubMedGoogle Scholar
  52. 52.
    Attal M, Huguet F, Schlaffer D et al. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood 79: 1130PubMedGoogle Scholar
  53. 53.
    Gianni AM, Tarella C, Siena Set al. (1990) Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Mar Transpl 6: 143Google Scholar
  54. 54.
    Jagannath S, Vesole DH, Gleen L et al. (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow transplantation and blood stem cell support. Blood 80: 1666PubMedGoogle Scholar
  55. 55.
    Cunningham D, Powles R, Malpas JS et al. (1993) A randomized trial of maintenance therapy with Intron-A following high-dose Melphalan and ABMT in myeloma. ASCO Proc 12: 364Google Scholar
  56. 56.
    Belch A, Shelley W, Bergsagel D et al. (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 57: 94PubMedCrossRefGoogle Scholar
  57. 57.
    Mandelli F, Avvisati G, Amodori S et al. (1990) Maintenance treatment with recombinant alpha-interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430PubMedCrossRefGoogle Scholar
  58. 58.
    Ludwig H, Cohen AM, Huber H et al. (1991) Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer 27: 40Google Scholar
  59. 59.
    Westin J (1991) Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish Multicentre Study. Sem Oncol 18: 37 (Suppl 7)Google Scholar
  60. 60.
    Salmon SE, Tesh D, Crowley Jet al. (1990) Chemotherapy is superior to sequential Hemibody Irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 8: 1575PubMedGoogle Scholar
  61. 61.
    Buzaid AC, Dude BGM (1988) Management of refractory myeloma: a review. J Clin Oncol 6: 889PubMedGoogle Scholar
  62. 62.
    Singer CRJ, Tobias JS, Giles FJ et al. (1989) Hemi-body irradiation — an effective second-line therapy in drug-resistant multiple myeloma. Cancer 63: 2446PubMedCrossRefGoogle Scholar
  63. 63.
    Giles FJ, De Lord C, Gaminara EJ et al. (1990) Systemic irradiation therapy of myelomatosis — the therapeutic implications of technique. Leuk Lymphoma 1: 227CrossRefGoogle Scholar
  64. 64.
    Salmon SE, Dalton WS, Grogan TM et al. (1991) Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44Google Scholar
  65. 65.
    Johnson WJ, Kyle RA, Pineda AA et al. (1990) Treatment of renal failure associated with multiple myeloma. Arch Intern Med 150: 863PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • F. J. Giles
  • B. G. M. Durie

There are no affiliations available

Personalised recommendations